PMP PALS' Network
  • Home
  • About Us
    • PMP Pals Are Unique!
    • PMP Pals in French
    • PMP Pals in German
    • PMP Pals in Italian
    • PMP Pals in Portuguese
    • PMP Pals in Spanish
    • We Protect Your Privacy
    • Memorials
    • Pals 2011 Budget Report
  • Join the "Pals" Today!
    • Testimonials about PMP Pals!
    • PMP Pals are unique!
    • We Protect Your Privacy
  • Blogs
    • Appendix Cancer Blog
    • Pseudomyxoma Peritonei Blog
  • Contact Us
  • Appendix Cancer
    • Appendix Cancer Patient Connections
    • Appendix Cancer Chemotherapy
    • Appendix Cancer Diagnosis
    • Appendix Cancer Diet and Exercise
    • Appendix Cancer Glossary
    • Appendix Cancer Research
    • Appendix Cancer Research Clinical Trials
    • Appendix Cancer Staging
    • Appendix Cancer Surgeons
    • Appendix Cancer Symptoms
    • Appendix Cancer Physicians
  • Appendix Cancer Survival Rate
    • Appendix Cancer Survivors
    • Appendix Cancer Statistics
    • Coping with Appendix Cancer
  • Appendix Cancer Treatment
    • Appendix Cancer HIPEC Treatment
    • Appendix Cancer Surgery
    • Appendix Cancer Specialists
    • Appendix Cancer Systemic Chemotherapy
  • Clinical Trials
  • Conferences and Events
    • Appendix Cancer Conferences
    • Pseudomyxoma Peritonei Conferences
    • PMP Pal Conferences
    • Pals' Conference Interest Form
    • PMP Pals Conference Venue
    • PMP Pals Family Fun Day!
    • PMP Pals' Community Services
    • PMP Pals Heat it to Beat it!
  • Donations
    • Donate to PMP Research for a Cure
    • Donate Organs
    • Donate Medical Supplies!
  • Frequently Asked Questions
  • HIPEC Treatment
    • HIPEC Treatment Centers
    • HIPEC Patient Profiles
    • HIPEC Surgery Recovery
    • Colorectal Cancer and HIPEC
    • Dr Paul H Sugarbaker
    • HIPEC Insurance Questionnaire
    • HIPEC en Espanol>
      • HIPEC in Mexico
      • Registration for Spanish Speaking Surgical Oncologists
  • Mucinous Adenocarcinoma
  • Newsletter
    • Newsletter Directory
  • Nutrition and Exercise
    • Appendix Cancer Diet and Exercise
    • Celiac Disease Nutrition
    • Pseudomyxoma Peritonei Nutrition
  • Peritoneal Carcinomatosis
  • Peritoneal Surface Malignancies
    • Mesothelioma
    • Pancreatic Cancer
  • Pseudomyxoma Peritonei
    • DPAM
    • PMP Survivors
    • Pseudomyxoma Peritonei Diagnosis
    • Pseudomyxoma Peritonei Prognosis
    • Pseudomyxoma Peritonei Symptoms
    • Pseudomyxoma Peritonei Treatment
    • Pseudomyxoma Peritonei Surgery
    • Pseudomyxoma Peritonei Specialists
    • Pseudomyxoma Peritonei HIPEC
    • Pseudomyxoma Peritonei Chemotherapy
    • Pseudomyxoma Peritonei Survival
    • Pseudomyxoma Peritonei Survivors
    • Pseudomyxoma Peritonei Survival Stories!
    • Pseudomyxoma Peritonei Articles
    • Pseudomyxoma Peritonei Nutrition
  • Research
  • Signet Ring Cell Adenocarcinoma
  • Support
    • Patient Support Mentors
    • Appendix Cancer Support
    • Cancer Free Pals
    • Couples' Support Groups!
    • Family Support Groups!
    • Mens' Support Groups!
    • Pacific Rim Support Group
    • Womens' Support Groups!
    • Senior Services
    • Bereavement Support
    • Caregiving
    • Coping with Cancer
    • Financial Aid and Social Services
    • Financial Aid
    • Health Insurance
    • Health Insurance
    • Hospice Care
    • Recommended Reading
    • Recommended Reading
    • Transportation Services
  • Surgeons and Specialists
    • Appendix Cancer Surgeons and Specialists
  • Surgery
    • Frequently Asked Questions
    • Fistula Management
    • G Tube Gastrostomy
    • Infection Prevention
    • Laparoscopy Minimally Invasive
    • Obstructions
    • Ostomies
    • Pseudomyxoma Peritonei Surgery
    • Surgery Special Needs
    • Surgeons and Specialists>
      • HIPEC Treatment Centers
      • Dr Paul H Sugarbaker

Alphabetical Index of Articles by Appendix Cancer, Colorectal Cancer and Pseudomyxoma Peritonei Treatment Specialists

Picture

Click here for names and contact info for surgeons and specialists.


We provide the following listing of abstracts and articles, published by, and/or written about the world's most experienced international surgeons and specialists in the treatment and research of Pseudomyxoma Peritonei, and Appendix Cancer. The full titles of some abstracts have been abbreviated due to space limitations.
 
Alpha listings by surname:

Articles by Dr Syed Ahmad, USA

Title: VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.

Abstract

BACKGROUND: High levels of vascular endothelial growth factor (VEGF) in ovarian cancer metastases are associated with a worse prognosis in patients treated with chemotherapy. VEGF-directed therapy improves survival for those with metastatic colorectal cancer. Patients with mucinous adenocarcinomas metastatic to the peritoneal surfaces can be treated with cytoreductive surgery, and both tumor grade and cytoreduction status are prognostic. We hypothesized that angiogenic indices may be prognostic in patients undergoing cytoreductive surgery for mucinous adenocarcinoma of the appendix and colon.

METHODS: Cytoreductive cases from a 5-year period from the University of Cincinnati peritoneal malignancy database were reviewed. CD 34 counts (blood vessels) and VEGF expression was evaluated by means of immunohistochemistry on specimens from patients undergoing cytoreductive surgery and intraperitoneal hyperthermic perfusion (IPHP) for mucinous adenocarcinoma.

RESULTS: A total of 26 males and 9 females, with a mean age of 50 years, underwent cytoreductive surgery and IPHP for mucinous adenocarcinoma of appendiceal (n = 32) or colonic (n = 3) origin. With a mean follow-up of 18 months (range 1-63 months), 23 had disease recurrence and 12 were alive without recurrence. The mean survival was 19 months (range 1-63 months). CD34 counts did not correlate with recurrence or survival; however, average VEGF counts correlated with survival (P = 0.017), and, for patients with recurrence, this correlation was stronger (P = 0.002).

CONCLUSIONS: These results suggest that markers of tumor angiogenesis may predict survival in patients with peritoneal surface metastases from mucinous adenocarcinoma. These findings provoke the hypothesis that antiangiogenic therapies may be effective in patients with this devastating disease.

Source:Ann Surg Oncol. 2008 Mar;15(3):738-44. Epub 2007 Nov 28.

Current  concepts in the surgical management of pancreatic cancer
Source: Surg Oncol Clin N Am. 2010 Apr;19(2):335-58. Review.PMID: 20159518

Articles by Dr SA Ahrendt, USA

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008

CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgical Oncology, Nov 2008

Abstracts by Dr Dario Baratti, Italy

Pseudomyxoma Peritonei

Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009


Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
 
Journal of Clinical Oncology, vol. 30, no. 20, pp. 2449–2456, 2012


Importance of gender in diffuse malignant peritoneal mesothelioma
 
Annals of Oncology, vol. 23, no. 6, pp. 1494–1498, 2012


Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: A controlled study
 
Annals of Surgical Oncology, vol. 19, no. 5, pp. 1416–1424, 2012


Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies
 
Annals of Surgery, vol. 255, no. 2, pp. 348–356, 2012


Erratum: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement (Annals of Surgical Oncology 14 (128-133)DOI: 10.1245/s10434-006-9185-7)
 
Annals of Surgical Oncology, vol. 18, no. SUPPL. 3, pp. S334–S335, 2011


Erratum: Peritoneal sarcomatosis: Is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? (Annals of Surgical Oncology DOI: 10.1245/S10434-010-1178-X)
 
Annals of Surgical Oncology, vol. 18, no. SUPPL. 3, pp. S327, 2011


Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial
 
Gynecologic Oncology, vol. 122, no. 2, pp. 215–220, 2011


Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research
 
Journal of Surgical Oncology, vol. 103, no. 8, pp. 822–831, 2011


Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer
 
European Journal of Surgical Oncology, vol. 37, no. 1, pp. 4–9, 2011


Peritoneal sarcomatosis: Is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
 
Annals of Surgical Oncology, vol. 17, no. 12, pp. 3220–3228, 2010


Multicystic peritoneal mesothelioma: Outcomes and patho-biological features in a multi-institutional series treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
 
European Journal of Surgical Oncology, vol. 36, no. 11, pp. 1047–1053, 2010


Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma
 
European Journal of Cancer, vol. 46, no. 15, pp. 2837–2848, 2010


In reply: Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesothelioma
 
Annals of Surgical Oncology, vol. 17, no. 6, pp. 1713–1714, 2010


Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)
 
European Journal of Surgical Oncology, vol. 36, no. 5, pp. 463–469, 2010


Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infection
 
Tumori, vol. 96, no. 2, pp. 340–344, 2010


Lymph node metastases in diffuse malignant peritoneal mesothelioma
 
Annals of Surgical Oncology, vol. 17, no. 1, pp. 45–53, 2010


Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience
 
Journal of Clinical Oncology, vol. 27, no. 36, pp. 6237–6242, 2009


Circulating CA125 and diffuse malignant peritoneal mesothelioma
 
European Journal of Surgical Oncology, vol. 35, no. 11, pp. 1198–1199, 2009


Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies
 
Journal of Surgical Oncology, vol. 100, no. 4, pp. 321–328, 2009


Pseudomyxoma peritonei: Biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy
 
Annals of Surgery, vol. 249, no. 2, pp. 243–249, 2009


Articles by Dr David L Bartlett, USA

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Anuals of Surgical Oncology, 2008

HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008

Dr David L Bartlett, Dr James Pingpank, Dr Steven Ahrendt
Source: Koch Cancer Treatment Center, UPMC

Profile for Dr David L Bartlett
Source: UPMC

Dr David L Bartlett:
Koch Cancer Center
Source: UPMC

Dr David L Bartlett: Treatment of Liver Cancer
Source: UPMC Koch Cancer Center

Articles by Dr Jean Bereder, France

Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
 
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010

Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010

Articles by Dr Wim Ceelen, Belgium

Dr Wim P Ceelen treats Pseudomyxoma Peritonei with HIPEC www.surgery.ugent.be

Articles by Dr Marcello Deraco, Italy

Pseudomyxoma PeritoneiBiological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009


HIPEC Treatment: Dott. Marcello Deraco: Pseudomyxoma Peritonei and Appendix Cancer
Source: Dott. Marcello Deraco

Articles by Dr D Elias, France

Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010

Articles by Dr Jesus Esquivel, USA

Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Limited Peritoneal Surface Malignancies: Feasibility, Morbidity and Outcome in an Early Experience.

Laparoscopic CRS and HIPEC in Patients with Limited PSMs

Source: Esquivel J, Averbach A, Chua TC  St. Agnes Hospital, Baltimore, Maryland.

Ann Surg. 2011 Jan 6. [Epub ahead of print]

Abstract

INTRODUCTION: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are being widely used in the treatment of patients with peritoneal surface malignancies. The open procedure has been associated with high grade III and IV morbidity and prolonged hospitalization.

METHODS: Patients with peritoneal surface malignancies and no gross evidence of carcinomatosis on the computed tomographic scan were enrolled to undergo laparoscopic CRS and HIPEC. We aimed to assess the feasibility, safety, and outcome of this procedure. Postoperative complications were reported according to the National Cancer Institute Common Toxicity Criteria.

RESULTS: From October 2008 to January 2010, 14 patients were enrolled into the protocol. Amongst these 14 patients, one patient was found with extensive carcinomatosis at the time of laparoscopy and had no surgical procedure. Thirteen patients had a complete cytoreduction and HIPEC, 10 (77%) laparoscopically and 3 (23%) were converted to an open procedure. There was one grade 3 morbidity (10%) and one patient (10%) in the laparoscopy group experienced a grade 4 complication, needing a reoperation for an internal hernia. Mean length of hospital stay was 6 days for those completed laparoscopically, 8 days for those converted to an open procedure and 8 days for a matched cohort of patients with an upfront open procedure.

CONCLUSIONS: This initial investigative stage demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic route in selected patients with low-tumor volume and no small bowel involvement mainly from appendiceal malignancies. Longer follow-up and additional studies are required to evaluate its long-term efficacy.

PMID: 21217512 [PubMed - as supplied by publisher]


Learning Curve for CRS and HIPEC
Source: Journal of Surgical Oncology, August 2009


Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009

HIPEC Treatment available at St Agnes Hospital
Source: Dr Jesus Esquivel

Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007

Physician Profile for Dr Jesus Esquivel
Source: St Agnes Hospital

Dr Jesus Esquivel:
St Agnes Hospital
Source: St Agnes Hospital

Articles by Dr Jan Franko, USA

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008

CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008

Click here to read Dr Jan Franko's profile

Articles by Dr Gilly, France

Study of 300+ Patients Treated with CRS and PIC :
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
 
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010

Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010

Articles by Dr Matthew Holtzman, USA

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008

Articles by Dr Joachim Jaehne, Germany

Cytoreductive Surgery Techniques
Source: Dr Joachim Jaehne, August 2009, Wiley


CRS:Stategies to Reduce Post Op Morbidity and Complications
Source: Dr Joachim Jaehne, April 2009


Articles by Dr Santiago Gonzalez-Moreno, Spain

Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009

Articles by Dr Martin Goodman, USA

Dr Martin Goodman at Tufts University provides HIPEC
Source: Tufts University, Boston

Articles by Dr Matthew Holtzman, USA

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008

CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008

Articles by Dr Daniel Labow, USA


Sarpel U, Bonavia AS, Grucela A, Roayaie S, Schwartz ME, Labow DM. Does Anatomic Versus Nonanatomic Resection Affect Recurrence and Survival in Patients Undergoing Surgery for Colorectal Liver Metastasis?. Annals of Surgical Onology 2008;.
Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, Schwartz ME. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008; 143(3): 366-374.

Cho CS, Labow DM, Gonen M, Jarnagin WR, D'Angelica M, Blumgart L, DeMatteo RP. Impact of Extent of Hepatic Resection for Metastatic Neuroendocrine Carcinoma. Cancer 2008 Jul 1; 113(1): 126-134.

Labow DM, Buell JF, Yoshida A, Rosen S, Posner MC. Isolated pulmonary recurrence after resection of colorectal hepatic metastases--is resection indicated?. Cancer J 8 2002; 8(4): 342-347.

Kammula US, Buell JF, Labow DM, Rosen S, Millis JM, Posner MC. Surgical management of benign tumors of the liver. Int J Gastrointest Cancer 2001; 30(3): 141-146.

Conlon KC, Labow D, Smith A, Jarnagin W, Coit DG, Merchant N, Brennan MF. A prospective randomized clinical trial of the value of intra-peritoneal drainage following pancreatic resection. Annals of Surgery 2001; 234(4): 487-494.

Kaneda Y, Liu D, Brooks A, Abolhoda A, Labow D, Burt ME, Ginsberg RJ. Toxicity and pharmacokinetics of isolated lung perfusion with cisplatin in rat. Japan Journal of Thoracic and Cardiovascular Surgery 2001; 49(7): 443-448.

Buell JF, Rosen S, Yoshida A, Labow D, Limsrichamrern S, Cronin DC, Bruce DS, Wen M, Michelassi F, Millis JM, Posner MC. Hepatic resection: effective treatment for primary and secondary tumors. Surgery 2000; 128(4): 686-693.

Labow D, Lee S, Ginsberg RJ, Crystal RG, Korst RJ. Adenovirus vector-mediated gene transfer to regional lymph nodes. Human Gene Therapy 2000; 11(5): 759-769.

Labow DM, Brennan MF. Gastric Cancer. In: Bayless , Diehl , editors. Advanced Therapy in Gastroenterology and Liver Disease 5/e. BC Decker Inc;.

Articles by Dr Laura Lambert, USA

CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield. 
See:
http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037


Articles by Dr Edward Levine, USA

CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008

“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.” 
Source: Annals of Surgical
Oncology,2007, Dr Edward Levine, WFU

Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006

DPAM and HIPEC Treatment
Source: Wake Forest University


Articles by Dr Brian W Loggie, USA

CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007

Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie


Gelatinous Ascites
: A Cytohistologic Study of Pseudomyxoma Peritonei in 67 Patients


Articles referring to Dr Brian Loggie's patients
Source: PMP Pals' Network


Articles by Dr Andrew Lowy, USA

Minimally Invasive Laparoscopic Surgery
Source: UCSD, Dr Andrew Lowy, 2009


Dr Andrew Lowy: Moores Cancer Center
Source: UCSD

Treatment of Pancreatic Cancer
Source: Dr Andrew Lowy UCSD

VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA.           Source:Ann Surg Oncol. 2008 Mar;15(3):738-44. Epub 2007 Nov 28.

Articles by Dr Paul Mansfield, USA

Profile for Dr Paul Mansfield
Source: MD Anderson

CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms

Source: Dr Paul Mansfield, ASCO 2008

CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source:
Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield. 
See:
http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037

Laparoscopic Staging for Gastric Cancer
Source: Dr Paul Mansfield, MDACC, Annals of Surgical Oncology, 2001


Laparoscopy for Surgical Oncology
Source: MDACC


Articles by Dr Brendan J Moran, United Kingdom


Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei.
Alves S, Mohamed F, Yadegarfar G, Youssef H, Moran BJ.

Pseudomyxoma Peritonei Centre, Basingstoke and North Hampshire Hospital Foundation Trust, Aldermaston Road, Basingstoke, Hampshire RG24 9NA, UK.

Abstract

BACKGROUND: Pseudomyxoma peritonei (PMP) is characterized by mucinous ascites, predominantly arising form a perforated tumour of the appendix. This study aimed to assess Health-Related Quality of Life (HRQL) in patients following cytoreductive surgery and intraperitoneal chemotherapy for PMP.

METHODS: Over a one year period, 49 consecutive patients (13 male, 36 females) with a median age of 55 (range 37-81 years) were enrolled. Patients were asked to complete the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire prior to surgery and at one, three, six and twelve months post-operatively.

RESULTS: 26 patients (53%) underwent complete cytoreduction and 20 (42%) patients had major tumour debulking. One patient died from progressive disease three months from surgery and two patients withdrew from the study within 6 months of surgery. Baseline questionnaire compliance was 100 per cent and remained high (overall 98% of eligible patients) during follow up. Grade III/IV morbidity occurred in 4 patients (9%). Patients undergoing both complete cytoreduction and major tumour debulking reported a clinically significant improvement in emotional well-being, appetite and global HRQL at 1 year following surgery.

CONCLUSION: Despite the high morbidity associated with cytoreductive surgery and intraperitoneal chemotherapy, an improvement in quality of life at 1 year following the procedure was seen following both complete cytoreduction and major tumour debulking. Longer term assessment is required to demonstrate the durability of this enhancement.

RS and HIPEC for the Treatment of Patients age 30-77 years
Source: North Hampshire Hospital, Basingstoke UK, 2007

Articles by Prof David L Morris, Australia 

Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes

Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Source: David L. Morris, MD, PhD 2009

Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan

DPAM: Peritonectomy Improves Survival

Source Prof David L Morris, 2009


Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009


Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009

Pseudomyxoma Peritonei Long Term Survival (10 year study) 
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, NSW, AU

Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience. 

This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.

In vivo model for Pseudomyxoma Peritonei research
Source: Prof David L Morris, Sydney Australia, 2009

Articles by Dr Stefaan Mulier, Belgium

Dr Stefaan Mulier provides HIPEC treatment for Pseudomyxoma Peritonei and Peritoneal Carcinomatosis 
Source: Leopold Park Clinic in Brussels


Articles by Dr Herwart Mueller, German

CRS for Senior Patients
Source: Dr Herwart Mueller, Germany

Articles by Dr Garrett M Nash USA

Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY

Articles by Dr Michael B Nicholl, USA

1. Nicholl M, Shilyansky J, Ota D. Management of malignant large bowel obstruction.
Contemp Surg 2002; August: 396-400.


2. Nicholl M, Pitt H, Wolf P, Cooney J, Kalayoglu M, Shilyansky J, Rikkers L. Choledochal
cysts in Western adults: complexities compared to children. J Gastrointest Surg
2004; 8:245-52.


3. Nicholl M, Lodge A, Brown I, Sugg S, Shilyansky J. Restored immune response to an
MHC-II restricted antigen in tumor-bearing hosts after elimination of regulatory T
cells. J Pediatr Surg 2004; 39:941-6.


4. Lodge A, Yu P, Nicholl M, Brown I, Jackson C, Schreiber K, Sugg S, Schreiber H,
Shilyansky J. CD 40 ligation restores cytolytic response and eliminates fibrosarcoma
in the peritoneum of mice lacking CD4+ T cells. Cancer Immunol Immunother 2006;
55:1542-52.


5. Nicholl MB, Bilchik AJ. Radiofrequency ablation of colorectal carcinoma liver
metastases. Curr Colorectal Cancer Rep 2007; 3:99-103.


6. Nicholl MB, Morton DL. Sentinel node biopsy in melanoma: standard of care. Am J
Hematol Oncol 2007; 6:468-471.


7. Nicholl M, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer?
Ann Surg Oncol 2008; 15:1-3.


8. Nicholl MB, Bilchik AJ. Thermal ablation of hepatic malignancy: useful but still not
optimal. Eur J Surg Oncol 2008; 34:318-23.


9. Huang SK, Darfler MM, Nicholl MB, You J, Bemis KG, Tegeler TJ, Wang M, Wery J,
Chong KK, Nguyen L, Scolyer RA, Hoon DSB. LC/MS-based quantitative proteomic
analysis of paraffin-embedded archival melanomas reveals potential proteomic
biomarkers associated with metastasis. PLoS ONE 2009;4(2): e4430.


10. Conway WC, Faries MB, Nicholl MB, Terando AM, Glass EC, Sim M, Morton DL. Age-
related lymphatic dysfunction in malignant melanoma patients. Ann Surg Oncol.
2009 Jun;16(6):1548-52.


11. Nicholl MB, Wright B, Conway WC, Aarnes-Leong T, Sim M, Faries M. Does
specialized surgical training increase lymph node yield in colon cancer? Am Surg
2009 Oct; 75(10): 887-91.


12. Nicholl MB, Conway WC, Ye X, Bilchik A, Singh G. Should Microwave Energy Be
Preferred to Radiofrequency Energy for Malignant Liver Tumor Ablation? J
Interventional Oncol 2010; 3(1): 12-16.


13. Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim M, Singh G. Small Bowel
Adenocarcinoma: Understaged and Undertreated? Ann Surg Oncol 2010;
17(10):2728-32.


14. Nicholl MB, Takeuchi H, Elashoff D, Morton DL, Hoon DSB. Molecular upstaging of
paraffin-embedded sentinel lymph nodes predicts long-term outcome in melanoma
patients. Ann Surg 2011;253(1):116-22.


15. Nguyen T, Kuo C, Nicholl MB, Sim M, Turner RR, Morton DL, Hoon DSB. Down-
regulation of MicroRNA-29c is Associated with Hypermethylation of Tumor-Related
Genes and Disease Outcome in Cutaneous Melanoma. Epigenetics. 2011 Mar 1;6(3).
[Epub ahead of print]


16. Fang J, Nicholl MB. Sirtulin 1 and malignant transformation: Friend or foe? Cancer
Lett. 2011 Mar 15. [Epub ahead of print]


17. Wheeler AA, Dale PS, Nicholl MB. Age influences likelihood of treatment, but not
outcome, in pancreatic cancer. In preparation


18. Macarthur K, Nicholl MB. Principles and innovations in peritoneal surface
malignancy treatment. In preparation.


Articles by Dr Haydee Ojeda-Fournier, USA   

Diagnostic Imaging of Pancreatic Cancer
Source: Dr Haydee Ojeda-Fournier, UCSD

Articles by Dr Evan Ong, USA

Greenstein SM, Delrio M, Ong E, Feuerstein D, Schechner R, Kim D, Corey H, Kaskel R, Tellis VA, Moritz ML. Plasmapheresis treatment for recurrent focal sclerosis in pediatric renal allografts. Pediatr Nephrol. 2000; 14 (12):1061-5.
 Babcock TA, Novak T, Ong E, Jho DH, Helton WS, Espat NJ. Modulation of LPS-stimulated macrophage TNF production by ω-3 fatty acid is associated with differential cyclooxygenase-2 (COX-2) enzyme translation and is independent of interleukin-10 (IL-10). Journal of Surgical Research 2002 Sep; 107 (1):135   Ong E, Helton WS, Espat NJ.Operative Experience of U.S. General Surgery Residents: Liver and Pancreas 1989-2001.Journal of Gastrointestinal Surgery. 2003 Feb;7(2):311 Ong E, Gao XP, Xu N, Predescu D, Rahman A, Broman MT, Jho DH, Malik AB. E. coli Pneumonia Induces CD-18 Independent Airway Neutrophil Transalveolar Migration In the Absence of Increased Lung Vascular Permeability. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2003 Oct;285(4):L879-88   Espat NJ, Ong E, Helton WS, Nyhus LM. 1990-2001 U.S. General Surgery Chief Resident Gastric Surgery operative Experience: Analysis of Paradigm Shift. Journal of Gastrointestinal Surgery. 2004 May-Jun;8(4):471-8 Ong E,Gao XP, Predescu D, Broman M, Malik AB. Phosphatidylinositol 3-Kinase Regulation of Neutrophil Extravasation: Role in Lung Inflammation. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2005 December; 289 (6): L1094-103.   Ong E, Jho D, Helton WS, Espat NJ. Surgisis®-assisted Delayed Repair of a Complex Bile Duct Injury after Laparoscopic Cholecystectomy. Journal of Gastrointestinal Surgery. 2006 February; 10(2): 202-6. Sharif S, Broman M, Babcock T, Ong E, Jho D, Rudnicki M, Helton WS, Espat NJ. A Priori Dietary {Omega}-3 Lipid Supplementation Results in Local Pancreatic Macrophage and Pulmonary Inflammatory Response Attenuation in a Model of Experimental Acute Edematous Pancreatitis (AEP). Journal of Parenteral and Enteral Nutrition. 2006 July-August; 30(4): 271-6.   Jho DH, Jho DJ, Chejfec G, Ahn M, Ong E, Espat NJ. Primary biliary B-cell lymphoma of the cystic duct causing obstructive jaundice. The American Surgeon. 2007 May; 73(5): 508-10. Ong EAlassas M, Bullard Dunn KM, Rajput A. Colorectal Cancer Surgery in the Elderly: Acceptable Morbidity? American Journal of Surgery. 2008 Mar; 195(3):344-8; discussion 348.   Brovkovych V, Gao XP, Ong E,Brovkovych S, Brennan ML, Su X, Hazen SL, Malik AB, Skidgel RA. Augmented iNOS Expression and Increased NO Production Reduce Sepsis-Induced Lung Injury and Mortality in Myeloperoxidase-Null Mice. American Journal of Physiology: Lung Cellular and Molecular Physiology. 2008 Jul;295(1):L96-103. Ong E, Alassas M, Bogner PN, Bullard Dunn KM, Chey WY, Gibbs J. Total Gastrectomy for Gastric Dysplasia in a patient with Attenuated Familial Adenomatous Polyposis Syndrome. The Journal of Clinical Oncology 2008 Jul 20;26(21):3641-2.

Articles by Dr Gloria Ortega-Perez, Spain

Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009


Articles by Dr James Pingpank, USA

Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009


Articles by Prof Pompiliu Piso, Germany

Peritoneal Carcinomatosis Treatment (Study) with Tumor Honing Peptides
Source: Dept of Radiology, Germany 2009

Peritoneal Carcinomatosis Prognosis following treatment with surgery and HIPEC
Source: Prof P Piso, 2009

CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008

HIPEC Study with laboratory rats
Source: Deutscher Krebskongress, 2004

Articles by Dr B Ronnett, USA

CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008

DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009

Articles by Dr Armando Sardi, USA

CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009

Published abstracts by Dr Armando Sardi
Source: Mercy Medical Center


Steps to Prepare for SurgerySource: Mercy Medical Center

Curriculum Vitae for Dr Armando Sardi
Source: Mercy Medical Center

Profile for Dr Armando Sardi
Source: Mercy Medical Center

Complete cytoreduction offers longterm survival in patients with peritoneal carcinomatosis from appendiceal tumors of unfavorable histology.
Source:J Am Coll Surg. 2009 Sep;209(3):308-12. Epub 2009 Jul 9.PMID: 19717034

Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Source: Ann Surg Oncol. 2008 May;15(5):1414-23. Epub 2008 Feb 26.PMID: 18299935

Articles by Dr Perry Shen, USA

Dr Perry Shen at WFU provides HIPEC
Source: Wake Forest University

Articles by Dr Paul H Sugarbaker, USA

Surgical Responsibilities in the Management of Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, June 2010, Pub Med

Mesenteric Cyst resulting in Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2010

Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009

Epithelial appendiceal neoplasms (abstract with availability to purchase article in full)
Source: The Cancer Journal, 2009

Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009

DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009

Management of mucinous urachal neoplasm presenting as Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2008

Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007

Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006

Cytoreductive Surgery (includes graphic illustrations) Source: Dr Paul H Sugarbaker

Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker

Appendix Cancer Prognosis
Source: Dr Paul H Sugarbaker, Washington Hospital Center

Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul H Sugarbaker, 2005

Atlas of Appendix Cancer(includes graphic illustrations)
Source: Dr Paul H  Sugarbaker


Articles referring to Dr Paul Sugarbaker and his patients
Source: PMP Pals' Network

Articles by Dr Jeffrey Sussman, USA

VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon.Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE, Ahmad SA.Division of Surgical Oncology, Department of Surgery, University of Cincinnati Medical Center, 234 Goodman St., ML #0772, Cincinnati, Ohio 45219, USA.             Source:Ann Surg Oncol. 2008 Mar;15(3):738-44. Epub 2007 Nov 28.

Articles by Dr Vicktor J Verwaal, Holland

Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008


Cytoreduction and HIPEC Treatment for Appendix Cancer and Pseudomyxoma Peritonei (pdf)
Source: Netherlands Cancer Institute, Prof VJ Verwaal, 2006

Articles by Dr Tristan Yan, Australia

Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009

Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan

Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009

Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007

Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006

Articles by Dr H Zeh, USA

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008

CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008

CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008

Articles by Dr F Zoetmulder, Holland

Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008



This webpage is sponsored by "Pal" Patricia Egan Myers

Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.

Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.

The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.

We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.

Individuals or organizations who plagiarize this copyrighted website will be prosecuted.


Updated 08.12.12

Copyright © 2012 by the PMP Pals' Network



[Treatment of pseudomyxoma peritonei is developing]

Lepistö A, Osterlund P, Järvinen HJ.

Duodecim. 2010;126(14):1693-9. Finnish. PMID: 20804088 [PubMed - in process]Related citations

Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients.

Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; the French Surgical Association.

Cancer. 2010 Aug 24. [Epub ahead of print]PMID: 20737573 [PubMed - as supplied by publisher]Related citations

Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation.

Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL.

J Am Coll Surg. 2010 Aug 20. [Epub ahead of print]PMID: 20729102 [PubMed - as supplied by publisher]Related citations

[Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis.]

Lim C, Tordjmann D, Gornet JM, Nemeth J, Valleur P, Pocard M.

Bull Cancer. 2010 Aug 6. [Epub ahead of print] French. PMID: 20693116 [PubMed - as supplied by publisher]Related citations

Primary peritonectomy/HIPEC for disseminated peritoneal adenomucinosis achieves much lower recurrence rates and better survival than secondary procedures.

Zhu KJ, Morris DL.

Surgeon. 2009 Dec;7(6):345-50.PMID: 20681377 [PubMed - indexed for MEDLINE]Related citations

Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy.

Winder T, Lenz HJ.

Oncologist. 2010;15(8):836-44. Epub 2010 Jul 23.PMID: 20656916 [PubMed - in process]Related citations

[Prognostic factors and reproductive outcomes of borderline ovarian tumors: a review of 186 patients]

Tao T, Cao DY, Yang JX, Huang HF, Wu M, Pan LY, Lang JH, Guo LN, Shen K.

Zhonghua Yi Xue Za Zhi. 2010 May 18;90(19):1304-8. Chinese. PMID: 20646576 [PubMed - indexed for MEDLINE]Related citations

Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.

Ryan DP, Engelman JA, Ferrone CR, Sahani DV, Lisovsky M.

N Engl J Med. 2010 Jun 24;362(25):2411-9. No abstract available. PMID: 20573930 [PubMed - indexed for MEDLINE]Related citations

Mesenteric cyst: report of a case-resulting in pseudomyxoma peritonei.

Zappa L, Sugarbaker PH.

Tumori. 2010 Mar-Apr;96(2):332-5.PMID: 20572595 [PubMed - indexed for MEDLINE]Related citations



[Peritoneal carcinosis can have as good a prognosis as primary colonic cancer, and should be managed according to evidence-based practice]

Graf W, Mahteme H.

Lakartidningen. 2010 May 12-25;107(19-20):1320. Swedish. No abstract available. PMID: 20556987 [PubMed - indexed for MEDLINE]Related citations

 

 



Copyright (c) 2013 PMP Pals' Network. All rights reserved. Website design by PMP Pals' Publishing. Information on this website is not intended as a substitute for licensed, professional medical advice. Each case is unique. Patients should seek the counsel of their own licensed, healthcare professional(s.)